Equities

Amicus Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Amicus Therapeutics Inc

Actions
  • Price (EUR)11.90
  • Today's Change0.20 / 1.71%
  • Shares traded--
  • 1 Year change+30.77%
  • Beta0.4283
Data delayed at least 15 minutes, as of Feb 17 2026 07:11 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2024202420232022
ASSETS
Cash And Short Term Investments250286294
Total Receivables, Net1018866
Total Inventory1196024
Prepaid expenses355040
Other current assets, total------
Total current assets505483424
Property, plant & equipment, net525860
Goodwill, net198198198
Intangibles, net172023
Long term investments------
Note receivable - long term------
Other long term assets141919
Total assets785778724
LIABILITIES
Accounts payable131515
Accrued expenses10913089
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total272335
Total current liabilities149168139
Total long term debt390388392
Total debt390388392
Deferred income tax----4.94
Minority interest------
Other liabilities, total526265
Total liabilities591618601
SHAREHOLDERS EQUITY
Common stock2.942.922.82
Additional paid-in capital2,9262,8362,665
Retained earnings (accumulated deficit)(2740)(2684)(2532)
Treasury stock - common------
Unrealized gain (loss)(0.21)(0.19)(0.12)
Other equity, total5.305.43(12)
Total equity194160123
Total liabilities & shareholders' equity785778724
Total common shares outstanding299294281
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.